| Name | Title | Contact Details |
|---|
Reservoir Center for Health & Rehabilitation is a healthcare facility that provides care for residents and their families.
Humans across the globe and of all walks of life want to live at their personal best, and are seeking more natural alternatives to feeling their best and getting the most out of life. Today, they are discovering the answer through natural cannabinoid products. At the same time, science and technology are unlocking the future potential of cannabinoids. We believe that cannabinoids, when used responsibly, have the power to enhance the full spectrum of well-being and to help us live healthier and happier lives. Parallel is improving the well-being of our consumers today through our proprietary, innovative brands, while planting seeds for the future through our robust innovation and high bar for business standards.
SkinCareRx is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
California-based Finesse Solutions brings Silicon Valley technology to bioprocessing. Better performance, integrated intelligence, and plug-and-play bioprocess flexibility are provided by Finesse SmartParts™. Our TruFluor® single-use sensors are unparalleled in the industry. Our G3 Universal™ controllers enable sophisticated cell culture or fermentation recipes to run on any size or brand of vessel. Our TruBio® software provides an easy-to-use interface for upstream bioprocessing that can harmonize old and new equipment, aggregate in-line and off-line data, and electronically facilitate global technology transfer. Finesse enables you to supercharge your R&D laboratory or scale-up to a cGMP SmartFactory with equal ease: we offer complete services, including commissioning and validation.
ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.